A Phase IB/II Study of Second Line Therapy With Panitumumab, Irinotecan and Everolimus (PIE) in Metastatic Colorectal Cancer With KRAS WT

Trial Profile

A Phase IB/II Study of Second Line Therapy With Panitumumab, Irinotecan and Everolimus (PIE) in Metastatic Colorectal Cancer With KRAS WT

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Jan 2017

At a glance

  • Drugs Everolimus (Primary) ; Irinotecan (Primary) ; Panitumumab (Primary)
  • Indications Carcinoma; Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PIE
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Jan 2017 Results (n=33) of biomarker substudy, presented at the 2017 Gastrointestinal Cancers Symposium
    • 11 Oct 2016 Results of expansion phase (n=40) assessing safety and efficacy presented at the 41st European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top